Donate Toggle Menu

Raising awareness: Journalists’ Award supports education about renal cancer
Bayer HealthCare and Kidney Cancer Association (KCA) honor outstanding medical reporting / Applications for European “Advances in Renal Cancer” Award can be submitted until March 1, 2011

Leverkusen, February 16, 2011 – According to current estimates of the European Cancer Observatory (ECO), each year more than 71,000 patients are newly-diagnosed with kidney cancer all over Europe.(1) With a mortality rate of over 40 percent, renal cell carcinoma is the most dangerous type of all urological tumors. That is why educating the public about the disease and promoting early detection is of pivotal importance. Especially, since early diagnosis improves the chances of recovery and can help to save the life of patients with renal cancer. The disease is especially insidious, because typical symptoms often appear at a very late stage and the tumor is, in many cases, only discovered by chance.

To support and promote journalistic reporting focusing on renal cell carcinoma and current medical developments, Bayer HealthCare and the Kidney Cancer Association (KCA) have announced the European “Advances in Renal Cancer” Journalists’ Award 2011. For the third time, the prize honors publications, in which journalists cover the issue of renal cancer in a critical, but yet objective manner. It is endowed with the sum of Euro 7,500 and awarded to reports which have been published in print media, radio, television, and film.

Journalists may submit their applications by March 1, 2011 directly to the Kidney Cancer Association – Project Office, P.O. Box 90 06 48, 51116 Cologne, Germany. Journalistic work submitted for this year’s award will be taken into account, if it was published between March 1, 2010, and February 28, 2011 in a European country. All entries are evaluated by an expert jury according to journalistic criteria. This year, amongst others, Professor Peter Mulders, Department of Urology, University Medical Center St. Radboud, Nijmegen (Netherlands), Dr. Bernard Escudier, Institut Gustave Roussy, Villejuif (France), and Torsten Hoffmann, Association of German Medical Journalists (VDMJ), Stuttgart (Germany) are going to view and assess the contributions. The statutes and comprehensive background material on renal cancer are available for download online at Bayer HealthCare’s press portal at

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 15,988 million (2009), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 53.400 employees and is represented in more than 100 countries. Find more information at

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

(1) European Cancer Observatory (ECO). Cancer Fact Sheet 2008.

Bayer HealthCare AG
Helmut Schäfers, Tel. +49 214 30-58308
E-Mail: mailto:[email protected]

The full story can be found in BayNews.